Redmile Group’s Ayala Pharmaceuticals, Inc. Common Stock AYLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-341,030
Closed -$372K 77
2022
Q2
$372K Sell
341,030
-108,701
-24% -$248K 0.01% 71
2022
Q1
$1.79M Sell
449,731
-218,085
-33% -$1.13M 0.06% 67
2021
Q4
$5.68M Hold
667,816
0.13% 64
2021
Q3
$7.57M Hold
667,816
0.13% 68
2021
Q2
$6.8M Hold
667,816
0.1% 76
2021
Q1
$7.29M Hold
667,816
0.1% 78
2020
Q4
$7.61M Buy
667,816
+1,150
+0.2% +$13.3K 0.09% 74
2020
Q3
$7.85M Hold
666,666
0.14% 72
2020
Q2
$6.69M Buy
+666,666
New +$9.26M 0.12% 71

Other funds holding AYLA

Redmile Group's AYLA Position: Q3 2022 in Review

Redmile Group sold out of Ayala Pharmaceuticals, Inc. Common Stock (AYLA) in Q3 2022, closing a stake of 341,030 shares — an estimated $372K sold.

Redmile Group first reported a position in AYLA in Q2 2020 and held it in 9 quarters. The position peaked at $7.85M in Q3 2020. 14 funds tracked by Wall St. Rank hold AYLA as of Q3 2022.

  • Redmile Group reported no remaining Ayala Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Redmile Group sold 341,030 Ayala Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $372K.
  • Redmile Group first reported a position in Ayala Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 9 quarters.
  • Redmile Group's Ayala Pharmaceuticals, Inc. Common Stock position peaked at $7.85M in Q3 2020.
  • 14 funds tracked by Wall St. Rank held Ayala Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Redmile Group's 13F filing for Q3 2022, filed 14 Nov 2022.